Combination treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs and targeted radiation for people with advanced colorectal cancer that has spread to a few spots. It aims to see if this approach works better than the current standard treatment after other therapies have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have stage IV colorectal cancer that has spread to a maximum of 5 spots, like in the liver or lungs.
- You must have already tried at least two prior treatments for your cancer.
- You need to have a measurable tumor that can be checked with scans.
- You should be in generally good health, able to care for yourself, and have adequate organ function.
- You must not have had certain immunotherapy drugs before, and you should not have active autoimmune diseases or severe lung conditions.
- You must not have major bleeding or clotting problems, and you must not have recently had major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy with three drugs (an immunotherapy, a chemotherapy pill, and a targeted therapy) for advanced colorectal cancer. It aims to see if this combination can shrink tumors and improve outcomes for people whose cancer has not responded to standard treatments.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for advanced colorectal cancer. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.